Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
Authors
Keywords
Minimum Inhibitory Concentration, Ceftazidime, Imipenem, Meropenem, AmpC
Journal
DRUGS
Volume 74, Issue 1, Pages 31-51
Publisher
Springer Nature
Online
2013-12-18
DOI
10.1007/s40265-013-0168-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
- (2013) David J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
- (2013) H. W. Boucher et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
- (2012) Bartolomé Moyá et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
- (2012) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response
- (2012) C. Jacqueline et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
- (2012) Jean Carlet et al. Antimicrobial Resistance and Infection Control
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
- (2011) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
- (2011) Catharine C. Bulik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae
- (2011) Emilia Titelman et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- CXA-101
- (2011) G. Perletti et al. DRUGS OF THE FUTURE
- Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators
- (2011) Adela M. Luján et al. PLoS One
- Pseudomonas aeruginosa: all roads lead to resistance
- (2011) Elena B.M. Breidenstein et al. TRENDS IN MICROBIOLOGY
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a New Cephalosporin, CXA-101 (FR264205), against -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
- (2010) Y. Ge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
- (2010) CLINICAL INFECTIOUS DISEASES
- Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients
- (2010) L. Zamorano et al. CLINICAL MICROBIOLOGY AND INFECTION
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- Designing New β-Lactams: Implications from Their Targets, Resistance Factors and Synthesizing Enzymes
- (2010) Kian-Sim Goo et al. Current Computer-Aided Drug Design
- Progress and Challenges in Implementing the Research on ESKAPE Pathogens
- (2010) Louis B. Rice INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus -lactamase-producing Enterobacteriaceae
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1
- (2010) E. Riera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance
- (2009) C. C. Bulik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains
- (2009) C. Juan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftaroline
- (2009) George G. Zhanel et al. DRUGS
- Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates
- (2009) David M. Livermore et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein
- (2009) Bartolomé Moya et al. PLoS Pathogens
- Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205
- (2008) Ayako Toda et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
- (2007) Kenji Murano et al. BIOORGANIC & MEDICINAL CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started